GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
4.380 USD   -7.79%
07:01aGritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/15Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
AQ
08/15Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Sector news Biopharmaceuticals
03:34aAustralian Shares Rise to 10-Week High as Wage Growth Continues
MT
02:58aAustralian shares rise after weak wage data, CSL caps gains
RE
08/16CSL FY22 Profit Declines as Pandemic Constrains Core Plasma Therapy Sales; Shares Down ..
MT
08/16Australia shares flat as miners offset CSL drag, NZ falls ahead of rates decision
RE
08/16TRANSCRIPT : CSL Limited, 2022 Earnings Call, Aug 17, 2022
CI
08/16Australia biotech giant CSL reports profit dip, flags cost spiral
RE
08/16CSL annual profit drops 6% as weak plasma collections bite
RE
08/16CSL Limited Provides Earnings Guidance for the Fiscal Year 2023
CI
08/16CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 S..
CI
08/16CSL Limited Reports Earnings Results for the Full Year Ended June 30, 2022
CI
08/16CSL Net Profit Falls, But Expects Growth For Coming Year
DJ
08/12WuXi Biologics Inc. Announces Change of Address of Principal Place of Business in Hong ..
CI
08/10CSL Completes Vifor Pharma Acquisition
MT
08/09UBS Starts Samsung Biologics at Buy With 1,070,000 Won Price Target
MT
08/05Nomura Adjusts WuXi Biologics' Price Target to HK$97.78 From HK$95.75, Keeps at Buy
MT
08/05S.Korean shares post third straight weekly gain
RE
08/01CSL Receives All Regulatory Approvals for Vifor Pharma Acquisition
MT
08/01GreenLight Biosciences and Samsung Biologics Completes First Commercial-Scale Engineeri..
CI
07/28Samsung Biologics' Net Income Jumps 25.1% in June Quarter
MT
07/26Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosi..
MT
07/26Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosi..
MT
07/26U.S. FDA accepts Biogen's ALS therapy for review
RE
07/26U.S. FDA grants priority review to Biogen's ALS drug
RE
07/26Biogen Inc. Announces FDA Accepts its New Drug Application and Grants Priority Review o..
CI
07/26Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS
DJ
07/22China’s Wuxi AppTec, Wuxi Biologics to Each Invest $1.4 Billion in Singapore
MT
07/21JPMorgan Raises Biogen's Price Target to $221 From $219, Neutral Rating Maintained
MT
07/21Goldman Sachs Raises Biogen's Price Target to $220 From $213, Maintains Neutral Rating
MT
07/21UBS Adjusts Biogen Price Target to $238 From $247, Maintains Buy Rating
MT
07/21Cowen Adjusts Biogen's Price Target to $270 From $285; Outperform Rating Kept
MT
07/21Truist Securities Adjusts Biogen's Price Target to $270 From $320, Reiterates Buy Ratin..
MT
07/21Needham Adjusts Biogen's Price Target to $250 From $262, Reiterates Buy Rating
MT
07/21Barclays Lowers Biogen's Price Target to $200 From $210, Maintains Equalweight Rating
MT
07/21RBC Cuts Price Target on Biogen to $259 From $264, Maintains Outperform Rating
MT
07/21ANALYST RECOMMENDATIONS : Tesla, Nike, Netflix, Idexx Laboratories, Biogen...
MS
07/21Wedbush Cuts Biogen's Price Target to $183 From $188 Amid 'Revenue Erosion;' Neutral Ra..
MT
07/20US Stocks Close Higher Wednesday, Led by Consumer Discretionary, Tech
MT
07/20US Stocks Close Higher Wednesday Despite Steeper-Than-Expected Existing-Home Sales Decl..
MT
07/20Biogen Faces Declining Sequential Revenue Despite Positive Q2 Results, Wedbush Says
MT
07/20Biogen Shares Decline After Company Reports Lower Q2 Profits, Revenue
MT
07/20TRANSCRIPT : Biogen Inc., Q2 2022 Earnings Call, Jul 20, 2022
CI
07/20Biogen Reports Lower Q2 Profits, Revenue
MT
07/20Biogen leans on new Alzheimer's drug to calm investor worries
RE
07/20Biogen profit more than doubles on Samsung Bioepis stake sale
RE
07/20Biogen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 3..
CI
07/20Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.
CI
07/20Biogen Inc. Updates Earnings Guidance for Full Year 2022
CI
07/19Samsung Biologics to Add a Second Manufacturing Campus Near Seoul
MT
07/19WuXi Biologics Sees Up to 38% Jump in H1 Profit
MT
07/18WuXi Biologics Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022
CI
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on GRITSTONE BIO, INC.